Kornimate/medical-research-clean huggingface dataset:
use of repetitive facilitative exercise program in established stroke

Conditions: Stroke

Summary: the purpose of this study is to assess whether a novel therapy approach (repetitive facilitative exercise (rfe)) is more effective than conventional rehabilitation in facilitating the recovery of upper extremity function following stroke.


Eligibility criteria:
inclusion criteria: * age greater than 18 years * having a single ischemic or hemorrhagic hemispheric stroke of more than 6 months duration * the ability to selectively demonstrate active extension of at least 10 degrees at the metacarpo-phalangeal joint and the interphalangeal joints and 20 degrees at the wrist * capable of effectively participating in the study exclusion criteria: * upper extremity contracture/pain that interfere with study technique * pre-existing upper extremity neurologic or orthopedic disorders * unstable medical condition * bmi \> 35 * active treatment of condition during 3 months prior to enrollment in study (botulinum toxin, therapy, tendon release, etc.) * language or cognitive/perceptual deficits or scheduling problems that would limit participation * inability to provide informed consent

Keywords: stroke weakness rehabilitation chronic stroke
tadalafil for sarcoidosis associated pulmonary hypertension

Conditions: Pulmonary Hypertension

Summary: this study is designed to assess safety and efficacy of tadalafil in patients with sarcoidosis associated pulmonary hypertension. hypothesis: tadalafil is safe and effective in treating pulmonary hypertension in patients with sarcoidosis


Eligibility criteria:
inclusion criteria: * biopsy proven sarcoidosis * mean pulmonary artery pressure \> 25 mmhg at rest or greater than 30 mmhg with exercise by right heart catheterization within 1 year prior to entry into study * pulmonary capillary wedge pressure ≤ 15 mmhg * pvr values ≥ 3.0 woods units * forced vital capacity (fvc) \> 40% predicted * forced expiratory volume in 1 second (fev1) \> 40% predicted * who functional class ii or iii * stable sarcoidosis treatment regimen for three months prior to entry into study * 6 minute walk distance between 150-450 meters * stable dose of antihypertensive medications * on no other medication to treat pah (sildenafil, vardenafil, treprostinil, epoprostenol, iloprost, bosentan, ambrisentan) within one month prior to enrollment and during duration of the study * non-pregnant females exclusion criteria: * exercise limitation related to a non-cardiopulmonary reason (e.g. arthritis) * severe systemic hypertension \> 170/95 * severe systemic hypotension \< 90/50 * history of priapism * patients with congestive heart failure (left ventricular dysfunction) lvef \< 45% by echocardiogram * anticipation by the investigator for escalation in sarcoidosis treatment during the course of the study * pulmonary hypertension related to etiology other than sarcoidosis (i.e. hiv, scleroderma, chronic thromboemboli) * use within 1 month of an sildenafil or vardenafil * who functional class iv status * patients with severe other organ disease felt by investigators to impact on survival during the course of the study * subjects with liver function abnormalities (alt or ast \> 3 times the upper limit of normal at screening or at baseline) or chronic liver disease * advanced kidney failure (gfr \< 30 ml/min at screening or at baseline) * history of hypersensitivity reaction or adverse effect related to tadalafil * pregnant or lactating women * concomitant use of nitrates (any form) either regularly or intermittently * concomitant use of potent cyp3a inhibitors (eg, ritonavir, ketoconazole, itraconazole) * any additional contraindications and precautions specified in the package inserts for tadalafil (adcirca) not listed above

Keywords: sarcoidosis associated pulmonary hypertension
chemotherapy and irreversible electroporation in the treatment of advanced pancreatic adenocarcinoma

Conditions: Pancreas Cancer

Summary: compare the efficacy and tolerability of ire in combination with either folfirinox or gemcitabine in patients with locally advanced pancreatic cancer.

phase ii study in which all patients undergoing ire for the treatment of locally advanced pancreatic carcinoma will receive either folfirinox or gemcitabine as peri-ablation treatment.

Eligibility criteria:
inclusion criteria: * greater than or equal to 18 years of age * diagnosed with stage iii pancreatic cancer * tumor is measurable * gfr \> ml/min/1.73m2 * willing and able to comply with protocol requirements * ast/alt \>3 times upper limit of normal * stable surgical post-operative course as defined by operative surgeon exclusion criteria: * participating in another clinical trial for the treatment of cancer at the time of screening * pregnant or currently breast feeding * have a cardiac pacemaker or icd implanted that cannot be deactivated during ire procedure * have non-removable implants with metal parts within 1 cm of the target lesion * had a myocardial infarction within 3 months prior to enrollment
validation of laser doppler flowmetry to identify allergic rhinitis patients with pharmacogenetic alterations in histamine metabolism

Conditions: Allergic Rhinitis

Summary: the hypothesis to be proven is that histamine iontophoresis with measurement of microvascular blood flow by laser doppler flowmetry can be used as a reliable marker to characterize the normal microvascular cutaneous response to histamine.

the specific aim of this study is to validate iontophoresis (with measurement of microvascular blood flow by laser doppler flowmetry) in a pediatric cohort as a surrogate marker capable of reliably characterizing the normal physiologic response of the cutaneous microvasculature to histamine. in future studies laser doppler flowmetry ultimately will be used to assess whether microvascular blood flow determined by a previously validated laser doppler technique can be used as a reliable surrogate endpoint capable of functionally discriminating the effects of polymorphisms in the genes which are quantitatively important for histamine metabolism. the hypothesis to be proven is that histamine iontophoresis with measurement of microvascular blood flow by laser doppler flowmetry can be used as a reliable marker to characterize the normal microvascular cutaneous response to histamine.

Eligibility criteria:
inclusion criteria: -established diagnosis of allergic rhinitis and/or allergic conjunctivitis, and/or allergic asthma either clinically (by presence of rhinitis and/or conjunctivitis with or without associated wheezing) and/or with a positive rast/skin test to the following allergens: trees, grass, weeds, molds, cat, dog, dust mites and/or cockroach) exclusion criteria: * previous history or laboratory evidence of mccune albright syndrome, immunodeficiency, mastocytosis, receipt of immunomodulatory treatment, chronic conditions associated with abnormalities of the integument, hepatic or renal compromise, neoplastic disease, movement or neurologic disorders and uncontrolled adhd * active atopic dermatitis at the site of the skin prick test or site where histamine iontophoresis will be performed, i.e. active atopic dermatitis on anterior forearms * history of anaphylaxis or anaphylactic like episode * evidence of pregnancy (by urinary hcg) or lactation * use of drugs (within a specified time period) of agents capable of altering the response to histamine provocation (e.g., antihistamines, systemic corticosteroids, tricyclic antidepressants) * presence of any condition that, in the opinion of the investigator, would produce difficulty with adherence to study procedures.

Keywords: allergic rhinitis pharmacogenetics histamine
lower leg remote ischemic preconditioning in elective percutaneous coronary intervention (pci)

Conditions: Ischemic Heart Disease

Summary: the purpose of this study is to investigate if remote ischemic preconditioning by combining limb ischaemia with electric muscle stimulation of the ischemic muscle provokes better results in preconditioning the human heart than limb ischaemia alone does.

it has been demonstrated that protection from ischemia reperfusion can be achieved by brief periods of ischemia applied at a remote site during an injurious ischemic event (remote postconditioning). the purpose of this study is to investigate if the combination of brief periods of limb ischemia in combination with electric muscle stimulation at the same site could exceed the preconditioning effect of limb ischemia alone. therefore the investigators thought to perform 2 different forms of remote ischaemic preconditioning in patients undergoing elective coronary angioplasty. in the first patient group a blood pressure cuff will be applied at the lower leg. ischemia will be induced by inflating the cuff to a pressure of 200 mmhg for 5 minutes. afterwards reperfusion will be allowed for further 5 minutes. this cycle will be repeated 3 times. in a second patient group electric muscle stimulation at the same site (hitop 191) will be performed additionally throughout the whole preconditioning cycle. after preconditioning, the percutaneous coronary intervention (pci) will be performed by 3 pci-ballon inflations, each lasting for 2 minutes. between the inflations coronary reperfusion will be allowed for 5 minutes. the effects of preconditioning will be evaluated by analysing the st-deviation, caused by angioplasty in an intracoronary (derived by pci wire) and surface ecg. also the maximum of chest pain during the 3 inflation cycles and troponin levels 24 h after pci will be evaluated.

Eligibility criteria:
inclusion criteria: * planned pci of one of the main coronary artery (artery diameter distal of the stenotic area at least 2,5 mm) * patient age 18 years or older * stable angina pectoris symptoms exclusion criteria: * presence of collateral vessels * electrocardiographic bundle branch blocks * multiple coronary stenosis * occlusion of a coronary artery * renal insufficiency (gfr (mdrd) \< 50 ml/min/1,73 m2) * presence of coronary bypass grafts * history or presence of myocardial infarction. * echocardiographic signs of left ventricular hypertrophy (septal and/or posterior wall diameter greater than 14 mm) * some sort of medications (adenosine, morphine and derivates, immunosuppressive agents, oral antibiotics, theophyllin, alpha receptor blockers) * peripheral arterial disease * exercise tests performed within 24 h before study start.
features emotional responses in adults with autism: comparison with bipolar disorder (rembau)

Conditions: Autism Spectrum Disorder; Bipolar Disorder

Summary: the objective of this study is to identify the specific characteristics of autism spectrum disorder (asd) in emotional response profiles and shared with bipolar disorder (bd) characteristics.


Eligibility criteria:
inclusion criteria: * for all participants: * age between 18 and 50 years * normal vision (or corrected) * absence of neurological disorder (epilepsy , head trauma, ... ) * ability to understand information about the protocol * informed and signed consent * normal mood (euthymia) * normal or high intelligence * subjects with asd: * subjects with an autism spectrum disorder according to the dsm-5 * the diagnosis is confirmed by diagnostic interviews: adi- r (autism diagnostic interview-revised) and / or ados (autism diagnostic observation schedule ) . * subjects with bipolar disorder: * diagnosis of bipolar disorder according to dsm-iv-tr or dsm -5 * the diagnosis is confirmed by the mini 6.0 (the mini-international neuropsychiatric interview) . * healthy volunteers: * inclusion after checking the national register of healthy volunteers * no history of disease of the central nervous system or psychiatric disorder * no family history of asd or bd in the first degree * lack of psychotropic medication or current cardiotropic * lack of psychiatric disorder on axis i mini 6.0 * aq score \< 32

Keywords: autism spectrum disorder bipolar disorder emotions
oncolytic virus ad-td-nsil12 for progressive pediatric diffuse intrinsic pontine glioma

Conditions: Oncolytic Virus; Diffuse Intrinsic Pontine Glioma; Adverse Drug Event

Summary: this is a single-arm, single-center, drug safety assessment clinical trial with a 3+3 dose escalation design, to observe the safety, tolerability and toxicity of a novel oncolytic virus ad-td-nsil12 intratumoral injection in progressive dipg patients (nci-ctcae v5.0).


Eligibility criteria:
inclusion criteria: 1. informed consent of the parents or patient. 2. after surgical resection, biopsy, chemotherapy, or radiation therapy, tumor progression must be confirmed by mri scan. 3. biopsy is performed prior to injection of ad-td-nsil12 to confirm dipg (frozen section-based). 4. pre-enrollment patients lps (patients aged ≥1 and \<16 years) and kps (patients aged ≥16 years) ≥ 50. 5. patient must be, in the investigator opinion, able to comply with all the protocol procedures. 6. age 1-18 years. 7. a negative pregnancy test in fertile women (women are considered of childbearing potential (wocbp) after menarche, unless permanently infertile, including hysterectomy, bilateral salpingectomy, and bilateral oophorectomy). 8. lesion considered by the investigator to be accessible for stereotactic biopsy. exclusion criteria: 1. serious infections or intercurrent conditions, including but not limited to severe renal failure, liver failure, heart failure, or bone marrow failure, which are not permitted for inclusion according to the investigator's criteria. patients must be afebrile (\<38℃) at the time of viral therapy. 2. other investigational medications within 30 days prior to viral treatment. 3. participants with immunodeficiency, autoimmune disease, or active hepatitis. 4. any medical or psychological condition that might interfere with the patient's ability to participate if older than 16 years or parents ability when younger than 16, or give informed consent or would compromise the patient's ability to tolerate therapy or any disease that will obscure toxicity or dangerously alter drug metabolism. 5. tumor with multiple location. 6. pregnant or breast-feeding females. 7. severe bone marrow hypoplasia. 8. transaminases (aspartate aminotransferase (ast) and/or alanine aminotransferase (alt)) or total bilirubin \> 3 times the upper limit of normal. 9. neutrophils \< 1x10\^9/l. 10. platelets ≤ 100x10\^9/l. 11. hemoglobin \< 9g/dl. 12. patients with li-fraumini syndrome or a known germline defect in the retinoblastoma gene or its associated pathways. 13. administer any type of vaccine within 30 days prior to ad-td-nsil12 administration. 14. blood transfusions or drugs (such as g-csf) within 28 days before viral treatment to treat pancytopenia or other hematological disorders.
sympathoinhibition as a preferred second line treatment of obesity related hypertension

Conditions: Obesity; Hypertension

Summary: this study is designed to investigate whether sympathoinhibition with moxonidine could provide added metabolic benefit compared to the second line therapy in the current guidelines.

this is a randomised, double-blind, cross-over study. participants will be randomly assigned to receive either moxonidine 0.4mg daily or amlodipine 5mg and will later receive the alternate treatment. comprehensive testing will occur after each 12 week treatment phase and will include assessment of muscle sympathetic nerve activity, gut microbiome analysis and metabolic markers.

Eligibility criteria:
inclusion criteria: * age: 25 -70 years * (body mass index) bmi≥30kg/m2 * currently weight stable (+/- 3% in previous 6-12 months and not on any specific exercise or dietary program) * elevated clinic systolic (blood pressure) bp ≥135 or diastolic bp ≥85mmhg, * on ace inhibitor for at least 6 weeks prior to baseline assessment exclusion criteria: * grade 2-3 hypertension (systolic office bp \>160, diastolic office bp \>100 mmhg) * secondary causes of hypertension * ckd (chronic kidney disease) stage 4-5 {(estimated glomerular filtration) egfr\<30ml/min} * heart failure nyha (new york heart association) class ii-iv * recent cv (cardiovascular) event (acute myocardial infarction, acute coronary syndrome, stroke or transient ischaemic attack within the previous six months) unstable psychiatric condition * medication such as corticosteroids, several antidepressants and antipsychotics * female participants of childbearing potential must have a negative pregnancy test prior to treatment
hyperuricemia and left ventricular diastolic function

Conditions: Hyperuricemia; Metabolic Syndrome; Left Ventricular Diastolic Dysfunction

Summary: metabolic syndrome and hyperuricemia were both associated with inflammation, leading to diversities of cardiovascular disease such as left ventricular diastolic dysfunction, but the relationship among these entities remained unclear. the aim of the present study focuses on the association among hyperuricemia, diastolic dysfunction and inflammatory biomarkers in apparently healthy individuals with metabolic syndrome

apparently healthy individuals with metabolic syndrome were prospectively and consecutively enrolled since august 2017. blood samples were obtained after participants are fasting for at least 12 hours, including serum uric acid, high-sensitivity c-reactive protein, high-sensitivity interleukin-6, tumor necrotizing factor alpha, fasting glucose, glycosylated hemoglobin, insulin, lipid profile, creatinine, alanine aminotransferase, sodium, potassium, and calcium. all echocardiographic parameters were measured in accordance with the american society of echocardiography guidelines.

Eligibility criteria:
inclusion criteria: 1. age between 20 to 75 years 2. metabolic syndrome exclusion criteria: 1. left ventricular ejection fraction \<40% 2. severe valvular heart disease 3. significant structure heart diseases such as hypertrophic, dilated, infiltrative or restrictive cardiomyopathy, or congenital heart disease 4. persistent or chronic atrial fibrillation 5. status post cardiac surgery, including coronary artery bypass surgery of valve intervention 6. status post intra-cardiac device implantation 7. chronic obstructive pulmonary disease 8. severe anemia 9. an obvious systemic disease that interferes left ventricular diastolic dysfunction such as acute coronary syndrome

Keywords: hyperuricemia metabolic syndrome left ventricular diastolic dysfunction inflammation
study to evaluate a new device designed to collect heart activity and body movement data

Conditions: Epilepsy

Summary: this study is designed to collect data to support development of a novel product designed to sense changes in heart rate or movement during periods of sleep in people with epilepsy. when a potential seizure is detected, the system sends out an audio-visual notification.

this is a prospective, interventional, un-blinded, non-significant risk, multi-site study.

Eligibility criteria:
inclusion criteria: subjects must meet all of the following inclusion criteria: 1. five (5) years of age or older 2. caregiver capable of understanding and willing to comply with instructions provided in english for proper use of the study device as well as scheduled study visits. 3. guardian/parent for subjects less than 18 years or with cognitive limitation that would preclude consent must be willing and able to complete informed consent/and hipaa authorization. 4. a self-reported diagnosis of epilepsy. 5. currently taking at least one antiepileptic medication. caregivers must meet the following inclusion criteria: 1. eighteen (18) years of age or older 2. capable of understanding and willing to comply with instructions provided in english for proper use of the study device as well as scheduled study visits 3. willing and able to complete informed consent and hipaa authorization. exclusion criteria: subjects are not eligible to be enrolled in the study if they meet any of the following exclusion criteria: 1. any visible skin disorder, condition, or abnormal skin pigmentation which, in the investigators opinion, would interfere with the ability to wear the patch. 2. history of chronic dermatological, medical, or physical conditions that would, in the investigators opinion, preclude topical application of the test products and/or influence the outcome of the test. 3. known sensitivity or history of irritation to adhesive tape (latex) and/or topically applied products 4. an implanted defibrillator and/or pacemakers 5. severe psychiatric disease that in the investigator's judgment would prevent the patient's successful completion of the study. 6. pregnant and or nursing women (verified by a urine pregnancy test). 7. currently participating in another clinical study without sponsor approval. 8. caregiver that is unable to read instructions in the english language. exclusion criteria for caregiver: 1. under 18 years of age 2. not capable of understanding and willing to comply with instructions provided in english for proper use of the study device as well as scheduled study visits

Keywords: ecg accelerometer device
investigation of the cylex® immuknow® assay

Conditions: Leukemia; Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Hodgkin's Disease; Multiple Myeloma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Aplastic Anemia; Chronic Myelogenous Leukemia

Summary: currently, there is no accurate way of predicting the occurrence of graft vs host disease (gvhd) or infection. the purpose of this study is to analyze blood with the immuknow® assay to see if doctors can detect which patients are at risk for gvhd and for getting an infection before they occur.


Eligibility criteria:
inclusion criteria: patients who are undergoing allogeneic hsct using a myeloablative preparative regimen for any of the following disorders are eligible: 1. acute leukemia 2. non-hodgkin's lymphoma 3. chronic lymphocytic leukemia 4. hodgkin's disease 5. multiple myeloma 6. myelodysplastic syndromes 7. myeloproliferative disorders 8. aplastic anemia 9. chronic myelogenous leukemia
comparison of office-based ktp and co2 laser outcomes in patients with vocal cord lesions.

Conditions: Laryngeal Diseases

Summary: the purpose of this study is to test the outcomes of a co2 laser device called acupulse duo on vocal lesions and compare them to the most commonly used aura ktp laser in order to determine which device has the best results. the co2 laser device is an already fda approved device. however, there have been no studies comparing the two devices for this use.

a flexible laryngoscope is passed through the patient's nose. energy from the laser is delivered through a fiber. this unique quality allows the physician to thread the fiber through an endoscope and deliver energy. ktp is uniquely effective because the laser uses green light, which has an affinity with blood vessels. this means that the energy from the laser is absorbed more easily by blood vessels than other tissue. targeting the blood supply of a lesion causes the lesion to slough off, leaving the surrounding tissue undamaged. however, the properties of the ktp are not necessarily ideal, in that it penetrates deep into the vocal fold, risking scar formation. on the other hand, the co2 laser is absorbed by water found in soft tissues and is independent of tissue color. it is very precise and causes less damage of the deep tissues, which results in less swelling and faster recovery. the absence of a long healing process means that most patients can resume their normal activities even on the same day the co2 laser is the preferred laser for use in the operating room. the purpose of the study is to evaluate the fiber-based version of the co2 laser in the office setting.

Eligibility criteria:
inclusion criteria: * presence of laryngeal papillomatosis, hemorrhagic polyps, or leukoplakia/dysplasia of the vocal folds requiring in-office treatment. * has the capacity to provide consent exclusion criteria: * accutane (isotretinoin) within the past 6-12 months * history of keloid formation * demonstration of excessive or unusually prolonged erythema